Physician profile
Michael H Basista
NPI 1548257876
$132,174.90
in general payments reported to CMS, 2019-2025
37 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $8,248 · 2021: $9,582 · 2022: $12K · 2023: $13K · 2024: $28K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $8,455 · Travel and Lodging: $6,458 · Education: $19.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,095.50 |
| Food and Beverage | $8,454.67 |
| Travel and Lodging | $6,457.84 |
| Education | $19.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $75,502.62 | 2019-2025 | Epclusa |
| Madrigal Pharmaceuticals | $37,441.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $13,099.70 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,765.48 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $995.75 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $540.78 | 2019-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $442.28 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $343.11 | 2023-2025 | Zenpep, Vowst |
| Pfizer INC. | $304.10 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $241.10 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $151.97 | 2021-2023 | |
| Qol Medical, LLC | $133.79 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $126.66 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $126.59 | 2023 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $126.12 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $92.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $87.72 | 2022-2024 | Dificid |
| Celgene Corporation | $70.00 | 2022-2024 | Zeposia |
| Shire North American Group INC | $56.96 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $55.90 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $53.40 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $49.60 | 2023-2024 | Rebyota |
| Boston Scientific Corporation | $45.28 | 2020-2022 | |
| Braintree Laboratories, INC. | $44.61 | 2019-2024 | Sutab, Suflave |
| Shionogi INC | $41.07 | 2019 | |
| Organon LLC | $33.11 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.41 | 2023-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $27.85 | 2020-2021 | |
| Alfasigma USA, INC. | $26.36 | 2020-2021 | |
| Novo Nordisk INC | $23.22 | 2025 | Wegovy |
| Celltrion USA INC. | $19.89 | 2024 | Zymfentra |
| Medtronic, INC. | $18.56 | 2025 | Nexpowder |
| Sanofi Pasteur INC. | $14.93 | 2019 | |
| Redhill Biopharma INC. | $14.25 | 2021 | |
| Amgen INC. | $14.09 | 2022 | |
| Allergan, INC. | $12.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Basista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.